Clinical Bioequivalence Study of Drugs Used in COVID-19 Treatment Has Begun
30
March
Bioequivalence Studies of Ritonavir/Lopinavir and Favipiravir Successfully Completed
At Farmagen, which is currently the only active BE/BA clinical center in our country during the COVID process and one of the few centers worldwide, the bioequivalence studies of the molecules ritonavir/lopinavir and favipiravir have been successfully completed. Bioanalytical studies are continuing without interruption at the Novagenix Bioanalytical R&D Center, racing against time. This achievement will enable the affordable and adequate supply of these drugs, which are both difficult to procure and costly.
In a very short time, the bioequivalence study of umifenovir tablets will begin, and other equivalent candidates for favipiravir developed by our local manufacturers are waiting in line. We thank our solution partners and the authorities who have provided their support.
